头颈耳鼻咽喉部原发性结外非霍奇金淋巴瘤临床和免疫组化特征

目的：探讨头颈耳鼻咽喉部原发性结外非霍奇金淋巴瘤(PE-NHL)的临床及免疫表型特征。方法：回顾性分析155例头颈耳鼻咽喉部PE—NHL患者的临床资料，采用免疫组织化学技术复阅病理片改变。结果：临床表现原发器官缺乏特异性，体征以肿块或溃烂型最多。细胞免疫表型结果显示，来源于T细胞者占46．4％，来源于B细胞者占53．6％。其中鼻腔鼻窦以T细胞淋巴瘤为主，韦氏环则以B细胞淋巴瘤为多。结论：头颈耳鼻咽喉部PE-NHL临床过程复杂，特征缺乏特异性，诊断较难。对本病提高警惕，对可疑者反复活检，依据病理学和免疫组织化学改变结合临床特征可确诊。     

瘤内注射重组人p53腺病毒治疗晚期肺癌临床试验观察

目的 观察重组人p53腺病毒注射液(rAd-p53)在晚期肺癌治疗中的疗效和毒副反应。方法 12例IIIb-IV期肺癌及3例肺转移癌,CT定位经皮肺穿刺瘤内注射rAd-p53,1 次/周×4/疗程;通过临床观察、CT及病理对照及短期随访进行评价。结果 治疗后2 月观察肿瘤缩小5例(33.3%),无变化7例(46.7%),增大3例(20%);治疗后病理观察:癌组织坏死,癌细胞稀少(6/11,54.5%);除自限性发热外,无明显毒副反应。结论rAd-p53瘤内注射治疗肺癌,无明显毒副作用,能较好地抑制局部肿瘤的发展,尤其对失去手术机会,不能耐受放化疗的患者,是一种可行的有前景的方法。     

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.

PURPOSE: The unique immunoglobulin idiotype (Id) expressed by each B-cell lymphoma is a target for immunotherapy. Vaccination with Id induces humoral and/or cellular anti-Id immune responses. However, the clinical impact of these anti-Id immune responses is unknown. We and others have previously reported that immunoglobulin G Fc receptor (FcgammaR) polymorphisms predict the clinical response of lymphoma patients to passive anti-CD20 antibody infusions. In this study, we tested whether anti-Id immune responses or FcgammaR polymorphisms associate with clinical outcome of patients who received Id vaccination. PATIENTS AND METHODS: We analyzed 136 patients with follicular lymphoma who had received Id vaccination. The anti-Id immune responses were measured and FcgammaRIIIa and FcgammaRIIa polymorphisms were determined and correlated with clinical outcome for these patients. RESULTS: Patients who mounted humoral immune responses had a longer progression-free survival (PFS) than those who did not (8.21 v 3.38 years; P = .018). Patients with FcgammaRIIIa 158 valine/valine (V/V) genotype also had a longer PFS than those with valine/phenylalanine (V/F) or phenylalanine/phenylalanine (F/F) genotypes (V/V, 8.21 v V/F, 3.38 years; P = .004; v F/F, 4.47 years; P = .035). Multivariate analysis using the Cox proportional hazards model showed that V/V genotype and humoral immune responses were independent positive predictors for PFS. CONCLUSION: This study is the first to identify the predictive value of FcgammaR polymorphism on clinical outcome in patients who received active immunotherapy with tumor antigen vaccines. Our results imply that the antibodies induced against a tumor antigen are beneficial and that FcgammaR-bearing cells mediate an antitumor effect by killing antibody-coated tumor cells.     

Dietary beta-carotene absorption by blood plasma and leukocytes in domestic cats

Three experiments were conducted to study the uptake of oral beta-carotene by blood plasma and leukocytes in domestic cats. In Experiment 1, mature female Tabby cats (12 mo old) were given once orally 0, 10, 20 or 50 mg of beta-carotene and blood taken at 0, 12, 24, 30, 36, 42, 48 and 72 h after dosing. Concentrations of plasma beta-carotene increased in a dose-dependent manner. Peak concentrations were observed at 12-24 h and declined gradually thereafter. The half-life of plasma beta-carotene was 12-30 h. In Experiment 2, cats were dosed daily for six consecutive days with 0, 1, 2, 5 or 10 mg beta-carotene. Blood was sampled once daily at 12 h after each feeding. Daily dosing of cats with beta-carotene for 6 d resulted in a dose-dependent increase in circulating beta-carotene. Experiment 3 was designed to study the uptake of beta-carotene by blood leukocytes. Cats were fed 0, 5 or 10 mg of beta-carotene daily for 14 d. Blood leukocytes were obtained on d 7 and 14 to determine beta-carotene content in whole lymphocytes and in subcellular fractions. Blood lymphocytes took up large amounts of beta-carotene by d 7 of feeding. Furthermore, beta-carotene accumulated mainly in the mitochondria (40-52%), with lower amounts accumulating in the microsomes (20-35%), cytosol (15-34%), and nuclei (1.5-6%). Therefore, domestic cats readily absorb beta-carotene across the intestinal mucosa and transfer the beta-carotene into peripheral blood leukocytes and their subcellular organelles. beta-Carotene uptake kinetics show that some aspects of beta-carotene absorption and metabolism in cats are similar to those of humans.     

以VNTR作为多态标记检测人类白血病p53基因杂合子性缺失

用ＰＣＲ－ＶＮＴＲ多态分析，以白血病缓解期患者的骨髓有核细胞作为胚系对照，对２７例急性白血病患者进行ｐ５３基因杂合子性缺失进行检测，结果发现在２７例中１３例呈异质性，其胚系的多态性率为４８．２％（３／２７）。对１３例胚系的ＶＮＴＲ呈多态性的白血病患者（ＡＬＬ１０例，ＡＭＬ３例），进一步进行白血病细胞与胚系的ＰＣＲ－ＶＮＴＲ配对分析，结果发现１例ＡＬＬ患者白血病细胞的ＶＮＴＲ异质性消失，而呈均一性。提示此例ＡＬＬ患者ｐ５３基因缺失一条等位基因，呈ＬＯＨ。结果提示ｐ５３基因功能失活在急性淋巴细胞白血病的发病中可能起一定的作用。     

异环磷酰胺为主联合化疗方案治疗晚期非小细胞肺癌28例疗效观察

本文报告以异环磷酰胺为主联合化疗方案治疗晚期非小细胞肺癌28例，总有效率为35．7％。中位生存时间5月。主要毒副反应为骨髓抑制和脱发，发生率分别为100％和92．7％。其他毒副反应为肝功能损害和消化道反应，发生率分别为28．6％和28．6％。     

止痛活血化瘀药实验研究

本文研究了止痛活血化瘀药对血液流变性的影响。两类止痛活血化瘀药在改善红细胞聚集性、变形性等血液流变性诸参数的作用是明显不同的。结果表明活血散瘀类药可明显改善四项红细胞流变性参数，即通过降低红细胞表明电荷以增加细胞间的排斥力，防止红细胞聚集，改善变形性，降低纤维蛋白元含量，降低血液粘度，改善血液流变性。另一方面，祛风行气类药则可降低血小板聚集性和粘附性。因此，止痛活血化瘀药的作用机理是不同的     

国产榧属植物种子油含量及其脂肪酸测定

目的:分析了国产榧属植物种子油含量及其脂肪酸组成。方法:用重量法和GC法分别测定油含量和脂肪酸组成。结果:种子油含量在42.6%～54.39%;脂肪酸组成以亚油酸和油酸为主;不饱和脂肪酸占脂肪酸总量的76.1%～82.0%;饱和脂肪酸以山俞酸和棕榈酸为主。结论:榧属植物种子油属优质植物油,含量较高的山俞酸为特征性成分。对榧属植物种子油资源潜在的开发利用价值进行了评价。     

肺癌肺叶袖状切除术的安全性和有效性

目的:评价肺癌肺叶袖状切除术后患者的手术安全性和远期生存状况.方法:回顾分析了1999年10月至2003年12月行肺癌根治术的94名病例,其中肺叶袖状切除术11例(Ⅰ组),全肺切除术17例(Ⅱ组),肺叶切除术66例(Ⅲ组).通过比较三组术后气管插管时间、ICU停留时间、吻合口并发症率及围手术期死亡率,评价肺叶袖状切除术的手术安全性,比较Ⅰ、Ⅱ组间的生存期和转移复发率探讨其远期有效性.组间率比较用x2检验或Fisher精确检验,均数比较用t检验,生存分析用Kaplan-Meier法,生存曲线比较用Log rank检验.显著性差异标准α=0.05.结果:Ⅰ、Ⅱ、Ⅲ组的手术死亡率为0,11.8%,3.0%,组间无显著性差异;平均气管插管时间为0.5±2.3天,2.0±7.2天,0.6±4.1天(Ⅰ、ⅢVSⅡ组,P＜0.05);吻合口并发症率为3.0%,0,5.8%,组间无显著性差异.Ⅰ组1年、3年生存率为45.5%、32.5%,Ⅱ组为58.8%、45.8%.两组生存率、远期局部复发率和转移率无显著性差异.结论:肺癌肺叶袖状切除术具有和肺叶切除术相近的手术安全性,优于全肺切除术,而其复发转移率、远期疗效与后者相近,是安全有效的手术方式.